What is claimed is:

1. A compound of Formula I:



I

or a pharmaceutically acceptable salt thereof, in combination with an anti-PD-1 antibody for use in treating a cancer; wherein:

R^1 is NH_2 or CH_3;

R^2 is Cl, Br, CF_3, CH_3, or CN;

R^3 is H or F; and

n is 1 or 2.

2. The compound or salt for use according to claim 1 wherein:

(a) R^1 is NH_2; or.

(b) R^1 is CH_3.

3. The compound or salt for use according to any one of claims 1 to 2, wherein:

(a) R^2 is Cl; or

(b) R^2 is Br; or

(c) R^2 is CF_3; or

(d) R^2 is CH_3; or;

(e) R^2 is CN.

4. The compound or salt for use according to any one of claims 1 to 3, wherein:

(a) R^3 is H; or

(b) R^3 is F.

5. The compound or salt for use according to any one of claims 1 to 4, wherein:

(a) n is 1; or

(b) n is 2.

6. A compound selected from:

4-({2-[(Aminosulfonyl)amino]ethyl}amino)-*N*-(3-bromo-4-fluorophenyl)-*N*′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;

N-(3-Bromo-4-fluorophenyl)-*N*′-hydroxy-4-({2-[(methylsulfonyl)amino]ethyl}amino)-1,2,5-oxadiazole-3-carboximidamide;

4-({3-[(Aminosulfonyl)amino]propyl}amino)-*N*-(3-bromo-4-fluorophenyl)-*N*′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;

N-(3-Bromo-4-fluorophenyl)-*N*′-hydroxy-4-({3-[(methylsulfonyl)amino]propyl}amino)-1,2,5-oxadiazole-3-carboximidamide;

4-({2-[(Aminosulfonyl)amino]ethyl}amino)-*N*-(3-chloro-4-fluorophenyl)-*N*′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;

N-(3-Chloro-4-fluorophenyl)-*N*′-hydroxy-4-({2-[(methylsulfonyl)amino]ethyl}amino)-1,2,5-oxadiazole-3-carboximidamide;

4-({3-[(Aminosulfonyl)amino]propyl}amino)-*N*-(3-chloro-4-fluorophenyl)-*N*′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;

N-(3-Chloro-4-fluorophenyl)-*N*′-hydroxy-4-({3-[(methylsulfonyl)amino]propyl}amino)-1,2,5-oxadiazole-3-carboximidamide;

4-({2-[(Aminosulfonyl)amino]ethyl}amino)-*N*-[4-fluoro-3-(trifluoromethyl)phenyl]-*N*′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;

N-[4-Fluoro-3-(trifluoromethyl)phenyl]-*N*′-hydroxy-4-({2-[(methylsulfonyl)amino]ethyl}-amino)-1,2,5-oxadiazole-3-carboximidamide;

4-({3-[(Aminosulfonyl)amino]propyl}amino)-*N*-[4-fluoro-3-(trifluoromethyl)phenyl]-*N*′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;

N-[4-Fluoro-3-(trifluoromethyl)phenyl]-*N*′-hydroxy-4-({3-[(methylsulfonyl)amino]propyl}-amino)-1,2,5-oxadiazole-3-carboximidamide;

4-({2-[(Aminosulfonyl)amino]ethyl}amino)-*N*′-hydroxy-*N*-[3-(trifluoromethyl)phenyl]-1,2,5-oxadiazole-3-carboximidamide;

N′-Hydroxy-4-({2-[(methylsulfonyl)amino]ethyl}amino)-*N*-[3-(trifluoromethyl)phenyl]-1,2,5-oxadiazole-3-carboximidamide;

4-({3-[(Aminosulfonyl)amino]propyl}amino)-*N*′-hydroxy-*N*-[3-(trifluoromethyl)phenyl]-1,2,5-oxadiazole-3-carboximidamide;

N′-Hydroxy-4-({3-[(methylsulfonyl)amino]propyl}amino)-*N*-[3-(trifluoromethyl)phenyl]-1,2,5-oxadiazole-3-carboximidamide;

N-(4-Fluoro-3-methylphenyl)-*N*'-hydroxy-4-({2-[(methylsulfonyl)amino]ethyl}amino)-1,2,5-oxadiazole-3-carboximidamide;

4-({2-[(Aminosulfonyl)amino]ethyl}amino)-*N*-(3-cyano-4-fluorophenyl)-*N*′-hydroxy-1,2,5-oxadiazole-3-carboximidamide; and

N-(3-Cyano-4-fluorophenyl)-*N*′-hydroxy-4-({2-[(methylsulfonyl)amino]ethyl}amino)-1,2,5-oxadiazole-3-carboximidamide;

or a pharmaceutically acceptable salt thereof, in combination with an anti-PD-1 antibody for use according to claim 1.

7. 4-({2-[(Aminosulfonyl)amino]ethyl}amino)-*N*-(3-bromo-4-fluorophenyl)-*N*′-hydroxy-1,2,5-oxadiazole-3-carboximidamide, or a pharmaceutically acceptable salt thereof, in combination with an anti-PD-1 antibody for use according to claim 1.

8. 4-({2-[(Aminosulfonyl)amino]ethyl}amino)-*N*-(3-bromo-4-fluorophenyl)-*N*′-hydroxy-1,2,5-oxadiazole-3-carboximidamide, in combination with an anti-PD-1 antibody for use according to claim 1.

9. The compound or salt for use according to claim 1, where the compound is a solid form of 4-({2-[(aminosulfonyl)amino]ethyl}amino)-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide, which is:

(a) crystalline; or

(b) contains less than 2 % water.

10. The compound or salt for use according to claim 9, where the solid form has a melting point of 162 to 166 °C, ±3 °C.

11. The compound or salt for use according to claim 9, where the solid form has:

(a) at least one XRPD peak, in terms of 2-theta, selected from 18.4° ±0.2°, 18.9° ±0.2°, 21.8° ±0.2°, 23.9° ±0.2°, 29.2° ±0.2°, and 38.7° ±0.2°; or

(b) having at least two XRPD peaks, in terms of 2-theta, selected from 18.4° ±0.2°, 18.9° ±0.2°, 21.8° ±0.2°, 23.9° ±0.2°, 29.2° ±0.2°, and 38.7° ±0.2°; or

(c) having at least three XRPD peaks, in terms of 2-theta, selected from 18.4° ±0.2°, 18.9° ±0.2°, 21.8° ±0.2°, 23.9° ±0.2°, 29.2° ±0.2°, and 38.7° ±0.2°.

12. A compound of Formula F28:



F28

,

or a pharmaceutically acceptable salt thereof, in combination with an anti-PD-1 antibody for use in treating a cancer, wherein:

R^4 is F, Cl, Br, or I; and

n is 1 or 2.

13. 4-({2-[(Aminosulfonyl)amino]ethyl}amino)-*N*-[(4-bromo-2-furyl)methyl]-*N*′-hydroxy-1,2,5-oxadiazole-3-carboximidamide, or a pharmaceutically acceptable salt thereof, in combination with an anti-PD-1 antibody for use according to claim 12.

14. 4-({2-[(Aminosulfonyl)amino]ethyl}amino)-*N*-[(4-chloro-2-furyl)methyl]-*N*′-hydroxy-1,2,5-oxadiazole-3-carboximidamide, or a pharmaceutically acceptable salt thereof, in combination with an anti-PD-1 antibody for use according to claim 12.

15. The compound, salt, or solid form for use according to any one of claims 1 to 12, wherein said cancer is selected from melanoma, colon cancer, pancreatic cancer, breast cancer, prostate

cancer, lung cancer, brain cancer, ovarian cancer, cervical cancer, testicular cancer, renal cancer, cancer of the head and neck, lymphoma, and leukemia.

16. The compound, salt, or solid form for use according to any one of claims 7 to 11, wherein the cancer is melanoma.

17. The compound, salt, or solid form for use according to any one of claims 7 to 13, wherein the cancer is ovarian cancer.

18. The compound, salt, or solid form for use according to any one of claims 7 to 13, wherein the cancer is breast cancer.

19. The compound, salt, or solid form for use according to any one of claims 7 to 11, wherein the cancer is pancreatic cancer.

20. The compound, salt, or solid form for use according to any one of claims 7 to 11, wherein the cancer is prostate cancer.

21. The compound, salt, or solid form for use according to any one of claims 7 to 11, wherein the cancer is lung cancer.